In one case of a myeloid neoplasm, BNGOHM-0000149, OGM was able to uniquely identify a mosaic deletion of 3q13.31 to 3q22.3 overlapping GATA2, a gene associated with myelogenous leukemia and an Inc.lusion criterion for at least one clinical trial (NCT01861106), as well as complex rearrangements on 17p1, consisting of amplifications and deletions that impacted YWHAE, MNT, TP53, and MAP2K4 (Figure 4a). Here, TP53 is linked to myeloid neoplasm.